Welcome Message

  • The 14th AOCNMB 2022

It is a great honor for us to be appointed as the congress chair of the 14th Asia Oceania Congress of Nuclear Medicine and Biology. The conference will be held from September 6 (Tue.) to 7 (Wed.), 2022, at the The prince Kyoto Takaragaike in the form of Online-Onsite hybrid system. In recent years, the development of nuclear medicine in Asia and Oceania has been remarkable. In view of this, we have chosen the theme "Molecular Imaging, Imaging your Mind". It is our sincere pleasure to take this opportunity to serve as the chairman of this conference.

Among the various imaging modalities, the role of nuclear medicine has recently been greatly reevaluated. The reason for this is that the mechanism of tracer accumulation in nuclear medicine is based on physiological and biochemical evidence and is clearer than in other modalities. In the field of molecular imaging, in particular, it has become an indispensable modality for drug discovery and clinical trials of therapeutic agents, as it is unrivaled by other modalities due to advances in nuclear medicine equipment. This conference will feature symposia in this area. We hope many of you will join us.

  • Hiroshi Matsuda (Fukushima Medical University)
    Hiroshi Matsuda(Fukushima Medical University)
  • Yaming Li (China Medical University)
    Yaming Li(China Medical University)

AOCNMB 2022 Program at a glance

Speakers & Moderators

Neurology session

Sept. 6,2022 10:45-12:10

Supatporn Tepmongkol (Chulalongkorn University, Thailand)
Noriko Sato (National Center of Neurology and Psychiatry, Japan)
Tanyaluck Thientunyakit

Tanyaluck Thientunyakit

Faculty of Medicine Siriraj Hospital, Mahidol University (Thailand)

Education (with year of graduation)
  • 2000 M.D. Khon Kaen University, Faculty of Medicine (Medicine), Khon Kaen, Thailand
  • 2001 Internship, Prince of Songkla University (Internship), Hat Yai, Thailand
  • 2002 Diploma in Clinical Sciences in Radiology, Chulalongkorn University, Faculty of Medicine, Bangkok, Thailand
  • 2004 Nuclear Medicine, Chulalongkorn University, Faculty of Medicine, Bangkok, Thailand
  • 2010 Fellowship in PET (IAEA), Austin Health, Melbourne, Australia
Professional Career (with duration)
  • 2004-2009 Instructor and Assistant Professor, Faculty of Medicine, Prince of Songkla University, Thailand
  • 2009- present Associate Professor, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • 2004 – present Member, Nuclear Medicine Society of Thailand and Royal College of Radiologist (RCRT), Thailand
  • 2018 – present Committee, Collaborative Aging and Dementia Research Society Thailand
  • 2018 – present Associate member, European Society of Radiology (ESR)
  • 2018 – present Member, Society of Nuclear Medicine and Molecular Imaging
  • 2018 – present Member, Brain Imaging Council, Society of Nuclear Medicine and Molecular Imaging
  • 2018 – present Member, Radiological Society of Thailand (RST)
  • 2018 – present Member, Dementia Association of Thailand
  • 2019 – present Corresponding member and Ambassador to Thailand, European Society for Hybrid, Molecular and Translational Imaging
  • 2020 - present Member and Co-leaders in Science Communication Working Group, Thai Young Scientist Academy
  • 2020 - present Board Member, Brain Imaging Council, Society of Nuclear Medicine and Molecular Imaging
Publications in 5 years
  1. Thientunyakit T. F-18 FDG PET/CT scan helps in correct localization of primary esophageal cancer in a case of SCCA metastasis to the skull previously suspected from primary lung cancer. Siriraj Med J. 2017; 69:159-161.
  2. Thientunyakit T, Wongsurawat N, Hannantawiwat C, Nimmanit A. Relationship Between Fasting Blood Glucose Level and 18F-FDG PET/CT Biodistribution Quality in Patients with Cancer: How much should we concern? J Med Assoc Thai. 2017; 100:578-587.
  3. Thientunyakit T, Kaewput C, Ubolnuch K, Wangkawan T, Mali P. The Effect of a Shortened Fasting State Prior to Radiotracer Administration on Upper Abdominal Artifacts in Myocardial Perfusion Scan: A Pilot Study. Siriraj Med J. 2017; 69:268-275.
  4. Thientunyakit T, Sethanandha C, Muangpaisan W, Chawalparit O, Arunrungvichian K, Siriprapa T, et al. Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease: first-hand experience in Thailand. Nucl Med Commun. 2018; 39:186–192.
  5. Thientunyakit T, Minoshima S. Temporal muscle uptake causing an unusual focal artifact on 3D-SSP statistical maps of [18F]FDG brain PET in a patient with Alzheimer’s disease: A case report. World J Nucl Med. 2019. [Epub ahead of print]. DOI: 10.4103/wjnm.WJNM_97_18.
  6. Chawalparit O, Wontaneeporn N, Muangpaisan W, Thientunyakit T, Charnchaowanish P, Ngamsonbat C. MRI Hippocampal Subfield Volume Analysis: Comparison between Alzheimer’s Disease, Mild Cognitive Impairment, and Normal Aging Subjects in an Amyloid PET Project. J Alzheimers Dis Parkinsonism. 2019;9: 459.
  7. Wongngamrungroj A, Soongsathitanon S, Kanchanapiboon P, Thientunyakit T. Residual Radioactivity in Patients with Well-Differentiated Thyroid Cancer Receiving High Dose I-131 Therapy. J Med Assoc Thai. 2019; 102:1-8.
  8. Thientunyakit T, Thongpraparn T, Siriprapa T, Gelovani JG. Head-to-head comparison of 18F-Fluorodeoxyglucose and 18F-Fluorocholine PET/CT in three patients with rare gestational trophoblastic neoplasms. World J Nucl Med. 2020;19:72-77.
  9. Thientunyakit T, Sethanandha C, Muangpaisan W, Chawalparit O, Arunrungvichian K, Siriprapa T, Vichianin Y, et al. Relationships Between Amyloid Levels, Glucose Metabolism, Morphologic Changes in the Brain and Clinical Status of Patients with Alzheimer’s Disease. Ann Nucl Med. 2020;34:337-348.
  10. Thientunyakit T, Thiravit P, Mali P, Kanchanapiboon P. Benefit of Contrast-Enhanced PET/CT versus Non-Contrast-Enhanced PET/CT Relative to Lesion Detection, Lesion Characterization, and Diagnostic Accuracy in Patients with Cancer. J Med Assoc Thai 2020; 103:904-13.
  11. Minoshima S, Mosci K, Cross D, Thientunyakit T. Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders. Semin Nucl Med. 2021 May;51(3):230-240. doi: 10.1053/j.semnuclmed.2021.01.002. Epub 2021 Feb 2.
  12. Thientunyakit T, Thongpraparn T, Sethanandha C, Yamada T, Kimura Y, Muangpaisan W, Ishii K. Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. Jpn J Radiol. 2021 May 21. doi: 10.1007/s11604-021-01132-6. Online ahead of print.
  13. Kaewchur T, Chamroonrat W, Thientunyakit T, Khiewvan B, Wongsurawat N, Chotipanich C, et al. Thai National Guideline for Nuclear Medicine Investigations in Epilepsy. Asia Ocean J Nucl Med Biol. 2021; 9(2):1-19. Online ahead of print.
  14. Thientunyakit T, Sethanandha C, Muangpaisan W, Minoshima S. 3D-SSP analysis for amyloid brain PET imaging using 18 F-florbetapir in patients with Alzheimer's dementia and mild cognitive impairment. Med J Malaysia. 2021 Jul;76(4):493-501.
Clinical neuro PET research, how we started from scratch to international multicenter collaboration
Summary of Speech
The emerging advances in brain imaging using positron emission tomography (PET) allow for both visualization the direct effects of neuronal activity and quantitation of the rates of specific biological processes at the tissue level in vivo. Neuro PET imaging raises the possibility for the early detection of brain abnormality during preclinical phase and enable more accurate diagnosis, prognostic prediction and potentially the key for successful therapy. However, to establish Neuro PET imaging service and research requires a significant amount of resources, knowledge and skills. The speaker will share the milestone in developing neuro PET research under several challenging circumstances, from new radiotracer production, personnel training, reaching out to multidisciplinary team and funding agencies, collaboration with other involved parties in national and international levels to sustainably strengthen nuclear medicine neuroimaging in clinical service, education, and research. This experience-sharing session is aimed to inspire young and early-career professions, especially in the developing countries with limited facilities and human resources, who want to start brain research and collaborate with international partners/business sector but have no confidence to do so.
Nasreen Sultana

Nasreen Sultana

National Institute of Nuclear Medicine & Allied Sciences, BAEC (Bangladesh)

Education (with year of graduation)
  • Graduation in Medical sciences (MBBS) in 1993 Chittagong University.
  • Doctor of Medicine (MD) (Nuclear Medicine) in 2005 Bangabandhu Sheikh Mujib Medical University.
Professional Career (with duration)
  • Working as Associate Professor of Nuclear Medicine at the National Institute of Nuclear Medicine & Allied Sciences from April 2006 to June, 2015
  • Working as Professor of Nuclear Medicine at National Institute of Nuclear Medicine & Allied sciences from July 2015 to till date.
  1. Fellow of Asian Nuclear Medicine Board- 2016
  2. Certified in USG of early scan ( 11+-13+ weeks ) from Fetal Medicine Foundation, London -2013
  3. Registered Medical Physician from Bangladesh Medical & Dental Council- 1995
  4. WFUMB certified in advanced color Doppler Ultrasound -2005
  1. Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM) award in 2004, 2006 & 2009.
  2. World Federation of Ultrasound in Medicine & Biology (WFUMB) Education Fellowship award in 2005. Thomas Jefferson University, Jefferson Ultrasound Research & Education Institute. Caracas. Venezuela.
  3. World Federation of Nuclear Medicine & Biology (WFNMB) award for outstanding oral presentation in 2006 in Seoul.
  4. International Atomic Energy Agency (IAEA) fellowship award for Short term Scholar in Neuroimaging & Molecular imaging in 2017, University of Utah School of Medicine. Utah. USA
  5. Asian School of Nuclear Medicine fellowship award for visiting researcher in 2017, Osaka University Graduate School of Medicine. Osaka. Japan
  6. Travel Grant Award winner in 29th Congress of International Society of Ultrasound in Gynecology & Obstetrics (ISUOG) in Berlin, German. 2019.
Areas of Research Interest:
  1. Alzheimer’s disease, ApoE Genotyping, Neuroimaging, NPSLE, Relation of Vitamin D deficiency with cognitive impairment.
  2. Advanced Doppler Ultrasound Imaging.
  3. Brain imaging in Autism Spectral disorders
Publications in 5 years
  1. Relationship between Vitamin D Status and Brain Perfusion in Neuropsychiatric Lupus. Sultana, N., Sarkar, A.K., Matsuda, H. et al. Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s13139-022-00741-x
  2. In Differential Diagnosis of Dementia Application of Easy Z-score Imaging System in Single Photon Emission Computed Tomography Brain Perfusion Scan. Nasreen Sultana, Hiroshi Matsuda, Azmal Kabir Sarker, Jasmine Ara Haque, Rafiqul Islam. American Journal of Psychiatry and Neuroscience. Vol. 7, No. 4, 2019, pp. 100-107. doi: 10.11648/j.ajpn.20190704.14
  3. Prenatal sonographic diagnosis of congenital high airway obstruction syndrome. N. Sultana, A.K. Sarker, M. Asma, A. Sharmin, N. Mahbub, T.Parveen, S. Quddus, R. Parveen, T. Mandal Ultrasound in Obstetrics & Gynecology 2020; 56 (Suppl. 1): 57–378.Page 91.
  4. Antenatal diagnosis of aneurysmal malformation of the vein of Galen: a case report with the application of colour Doppler ultrasound. N. Sultana, T. Parveen, A.K. Sarker, S. Quddus, R. Parveen, A. Sharmin, M. Asma. Ultrasound in Obstetrics & Gynecology 2020; 56 (Suppl. 1): 57–378. Page 169
  5. Ultrasonography of twin reversed arterial perfusion sequence. R. Parveen,N. Sultana, A.K Sarker, S. Quddus, M. Asma, A. Sharmin, N. Mahbub, T. Parveen. Ultrasound in Obstetrics & Gynecology 2020; 56 (Suppl. 1):57–378. Page : 248
  6. The Journey of Alzheimer’s disease Diagnosis in Bangladesh and Current perspective. Short communication. Nasreen Sultana. EC Neurology 11.6(2019):390-393
  7. Deterministic Implication of Acetazolamide stress brain perfusion SPECT: A case Report. Azmal Kabir sarker. Nasreen Sultana, Fazle Elahy Miad, and Hiroshi Matsuda. EC Clinical and Medical Case reports 2.3(2019) : 75-80
  8. Role of Duplex Ultrasound for the Assessment of Malignancy in Breast Tumors. Anindita Rani Paul, Faria Nasreen, Nasreen Sultana January 2019.American Journal of Cancer Research 2019;7(4):143-149DOI: 10.11648/j.crj.20190704.14.
  9. Assessment of Agreement Between Peak Systolic Velocity of Inferior Thyroid Artery And Thyroid Scan In Differentiating Diffuse Toxic Goiter And Subacute Thyroiditis. Khaleda Mushtary, Nasreen Sultana and Sharmin Quddus. Bangladesh J. Nucl. Med. 2018 ;21(2):97-101. DOI: 10.3329/bjnm.v21i2.40359
  10. Cephalothoracopagus Conjoined Twin - Ultrasound Diagnosis at 26 Weeks. A Rare Case Report. Nasreen Sultana*, Nasrin Akter, Azmal Kabir Sarker and Tabassum Parvin.EC Clinical and Medical Case Reports 2.8 (2019): 83-87.
  11. Neurofibroma revealed as malignant peripheral nerve sheath tumor: a case report. Nasreen Sultana*, Azmal kabir Sarker, Sajedur Reza Faruquee, Mizanur Rahman, Jasmine Ara Haque. European Journal of Medical Case Reports. 2018 Volume 2(2):75-79. DOI: 10.24911/ejmcr/2/17
Radionuclide neuroimaging in dementia - current status in Bangladesh
Summary of Speech
Commencing in the early 1980s, the structural brain imaging in Bangladesh was adjoined by radionuclide neuroimaging in 1997, albeit remaining limited mostly within planar with occasional use of SPECT techniques. A chance to participate in the International Atomic Energy Agency's (IAEA) coordinated research project (CRP) in the field of neuroimaging has brought an upsurge F-18 FDG brain PET in Bangladesh over the past seven years. The IAEA CRP aided in the development of capabilities for interpretative analysis of 18F-FDG PET/CT brain images by using the 3D-SSP neurostat while utilizing the existing equipment and logistics at the National Institute of Nuclear Medicine and Allied Sciences, Dhaka. The easy z-score imaging system (eZIS), software released under the Asia Oceania Research Initiative Network (AORIN) Brain, has enhanced the development of interpretative skills of Tc-99m HMPAO and Tc-99m ECD based SPECT imaging among nuclear medicine physicians and trainees. Moreover, the CRP facilitated the correlative imaging using 3T brain MRI, and biomarkers like Apo E genotype which has advanced the standard of clinical management of Alzheimer's disease and other dementias in Bangladesh.
Despite the fact that there is presently no cure for neurodegenerative diseases, they typically require specialized care planning, symptomatic treatment plans, and support for caregivers and family members. This suggests that a more accurate differential diagnosis is necessary for better patient care.
Currently we are using our newly gained skills for the radionuclide neuroimaging of neuropsychiatric lupus and autism spectrum disorder.
Yu Kyeong Kim

Yu Kyeong Kim

Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul (South Korea)

Education (with year of graduation)
  • 1988. 3. 1. -1995. 2. M.D. in Seoul National University College of Medical, Seoul, Korea
  • 1999. 3. 1. -2001. 2. M.S. in Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
  • 2001. 3 – 2006.2 Ph.D. in Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
Professional Career (with duration)
  • 1997. 5 –1998. 2. Research Assistant, Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul Korea.
  • 1998. 3. –2002.2 Resident in Department of Nuclear Medicine. Seoul National University Hospital, Seoul Korea.
  • 2002. 3 – 2004.10 Research Fellow, Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University School of Medicine
  • 2004. 11 – 2007.8 Faculty, Department of Nuclear Medicine, Seoul National University Bundang Hospital. Gyeonggyi, Korea.
  • 2007. 9 – 2012.4 Assistant Professor, Department of Nuclear Medicine, Seoul National University Bundang Hospital. Gyeonggyi, Korea.
  • 2012.3 - present Professor, Department of Nuclear Medicine, Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Korea
Publications in 5 years
  1. Ko K, Yi D, Byun BS, Lee JH, Jeon SY, Kim YJ, Byeon G, Sung K, Han D, Lee Y, Joung H, Jung G, Lee J-Y, Kim H, Kim YK, Kang KM, Sohn C-H, Lee DY, KBASE research group. Cognitive reserve proxies, Alzheimer pathologies, and cognition. Neurobiol Aging, 2022 Feb;110:88-95
  2. Kwak S, Shin S, Ko H, Kim H, Oh DJ, Youn JH, Lee J-Y, Kim YK, A Comparison Between the Performances of Verbal and Nonverbal Fluency Tests in Discriminating Between Mild Cognitive Impairments and Alzheimer’s Disease Patients and Their Brain Morphological Correlates. Dement Neurocogn Disord. 2022 Jan;21:17-29
  3. Sohn BK, Byun MS, Yi D, Jeon SY, Lee JH, Choe MY, Lee DW, Lee J-Y, Kim YK, Sohn C-H, Lee DY, KBASE Research group. Late-Life Physical Activities Moderate the Relationship of Amyloid-β Pathology with Neurodegeneration in Individuals Without Dementia. J Alzhemeirs Dis. 2022;86:441-450
  4. Lee D, Park J-C, Jung KS, Kim J, Jang JS, Kwon S, Byun MS, Yi D, Byeon G, Jung G, Kim YK, Lee DY, Han S-H, Mook-Jung I. Application of QPLEX TM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition. Exp Mol Med. 2022 Jan;54:61-71
  5. Kim JW, Byun MS, Yi D, Lee JH, Kim MJ, Jung G, Lee J-Y, Kang KM, Sohn C-H, Lee Y-S, Kim YK, Lee DY, KBASE Research group. Serum zinc levels and in vivo beta-amyloid deposition in the human brain. Alzheimers Res Ther. 2021 Nov;13:190
  6. Oh DJ, Jung J-J, Shin SA, Kim H, Park S, Sohn BK, Koo BK, Moon MK, Kim YK, Lee J-Y. Brain Structural Alterations, Diabetes Biomarkers, and Cognitive Performance in Older Adults With Dysglycemia. Front Neurol 2021 Oct;12:766216
  7. Yoo D, Lee J-Y, Kim YK, Yoon EJ, Kim HJ, Kim R, Nam H, Jeon B. Mild cognitive impairment and abnormal brain metabolic expression in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2021 Sep;90:1-7.
  8. Kim R, Lee J-Y, Kim YK, Kim HJ, Yoon EJ, Shin JH, Yoo D, Nam H, Jeon B. Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression. Mov Disord. 2021 Aug;36:1889-1898.
  9. Shin JH, Lee J-Y, Kim YK, Yoon EJ, Kim H, Nam H, Jeon B. Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder. Neurology. 2021 Jul;97:e378-388.
  10. Kim M, Park S-W, Lee J-Y, Kim H, Rhim JH, Park S, Lee J-Y, Son H, Kim YK, Lee SH. Differences in Brain Morphology between Hydrocephalus Ex Vacuo and Idiopathic Normal Pressure Hydrocephalus. Psychiatry Investig. 2021;18;628-635.
  11. Kim S, Lee P, Oh TK, Byun MS, Yi D, Lee JH, Kim YK, Ye BS, Yun MJ, Lee DY. Jeong Y. Alzheimer’s Disease Neuroimaging Initiative; KBASE Research Group. Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[ 18 F]FDG PET. EJNMMI Res. 2021;11:56
  12. Kim HJ, Park J-C, Jung KS, Kim J, Jang JS, Kwon S, Byun MS, Yi D, Byeon G, Jung G, Kim YK, Lee DY, Han S-H, Mook-Jung I. Exp Mol Med. 2021 Jun;53:1046-1054.
  13. Byun MS, Park SW, Lee JH, Yi D, Jeon SY, Choi JH, Joung H, Ghim UH, Park UC, Kim YK, Shin SA, Yu HG, Lee DY, KBASE Research Group. Association of Retinal Changes With Alzheimer Disease Neuroimaging Biomarkers in Cognitively Normal Individuals. JAMA Ophthalmol. 2021 May;139:548-556.
  14. Byeong G, Byun MS, Yi D, Jee JH, Jeon SY, Ko K, Jung G, Lee J-Y, Kim YK, Lee Y-S, King KM, Sohn C-H, Lee DY, KBASE research group. Synergistic Effect of Serum Homocysteine and Diabetes Mellitus on Brain Alterations. J Alzheimers Dis. 2021;81;287-295.
  15. Park JE, Lee YJ, Byun MS, Yi D, Lee JH, Jeon SY, Hwang JY, Yoon H, Choe YM, Kim YK, Shin SA. Suk HW, Lee DY, KBASE research group. Differential associations of age and Alzheimer's disease with sleep and rest-activity rhythms across the adult lifespan. Neurobiol Aging. 2021 May;101;141-149.
  16. Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Ko K, Joung H, Jung G, Lee J-Y, Sohn C-H, Lee Y-S, Kim YK, Lee DY. Blood Hemoglobin, in-vivo Alzheimer Pathologies, and Cognitive Impairment: A Cross-Sectional Study. Front Aging Neurosci. 2021 Feb;13:625511.
  17. Kang SK, Shin SA, Seo S, Byun MS, Lee DY, Kim YK, Lee DS, Lee JS. Deep learning-Based 3D inpainting of brain MR images. Sci Rep. 2021 Jan;11:1673
  18. Park J-C, Jung KS, Kim J, Jang JS, Kwon S, Byun MS, Yi D, Byeon G, Jung G, Kim YK, Lee DY, Han S-H, Mook-Jung I. Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition. Alzheimers Res Ther. 2021 Jan: 13: 12
  19. Shin JH, Lee J-Y, Kim YK, Shin SA, Kim HJ, Nam HW, Jeon B. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology 2020 Decl 95(23);e3081-92.
  20. Kim JW, Byun MS, Lee JH, Yi D, Jeon SY, Sohn BK, Lee JY, Shin SA, Kim YK, Kang KM, Sohn CH, Lee DY; KBASE Research Group. Serum albumin and beta-amyloid deposition in the human brain. Neurology. 2020 Aug 18;95(7):e815-e826.
  21. Lee S-Y, Kim HJ, Lee JY, Kim JH, Lee DY, Mook-Jung I, Kim YH, Kim YK. Effects of Chronic Tinnitus on Metabolic and Structural Changes in Subjects With Mild Cognitive Impairment. Front Aging Neurosci. 2020 Nov 19;12:594282.
  22. Choi HY, Kim YK, Yoon EJ, Lee J-Y, Lee DS, Alzhemier’s Diesease Neuroimaging Initiative. Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease. Eur J Nucl Med Mol Imaging. 2020 Feb;47(2)403-412
  23. Shin C, Lee J-Y, Kim YK, Nam H, Yoon EJ, Shin SA, Kim H-J, Jeon B. Cognitive decline in association with hyposmia in idiopathic rapid eye movement sleep behavior disorder: a prospective 2-year follow-up study. Eur J Neurol, 2019 Nov;26(11):1417-1420
  24. Lee JY, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, Kim HJ, Jeon B. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. J Mov Disrod. 2019 May;12(2);103-112
  25. Lee J-Y, Lee H, You HB, Choi J-S, Jung H-Y, Yoon EJ, Kim H, Lee H-Y, Kim YK. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study. Neurotherapuetics. 2019 Apr;16(2):394-403.
  26. Yoon EJ, Lee J-Y, Nam H, Kim HJ, Jeon B, Jeong JM, Kim YK. A New Metabolic Network Correlated with Olfactory and Executive Dysfunctions in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Neurol, 2019 Apr;15(2):175-183
  27. Kim H, Kim YK, Lee JY, Choi AR, Kim DJ, Choi J-S. Hypometabolism and altered metabolic connectivity in patients with internet gaming disorder and alcohol use disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2019 Dec 20;95:109680.
Imaging Biomarker for Synucleinopathy related Neurodegeneration in REM Sleep Behavior Disorder
Summary of Speech
Idiopathic REM sleep behavior disorder (iRBD) is the prodromal stage of synucleinopathy related neurodegenerative diseases like Parkinson Disease (PD) or Dementia with Lewy Bodies (DLB). The development of validated biomarkers in iRBD reflecting clinical severity and predicting future phenoconversion can provide an opportunity to detect the earliest stages of the disease and to investigate the efficacy of early neuroprotective strategies. Hereby, we developed the disease-specific metabolic brain network of RBD-related metabolic pattern (RBDRP) derived from the iRBD patients as well as de novo PD with RBD symptom, and observed the longitudinal change in RBDRP expression and their prognosis. We found that the RBDRP from de novo PD (dnPDRBDRP) is an efficient neuroimaging biomarker that reflects prodromal features of PD and predicts phenoconversion in iRBD that can be applied individually.

Cardiology session

Sept. 7,2022 8:30-10:30

Guang-Uei Hung (Chang Bing Show Chwan Memorial Hospital, Taiwan)
Kenichi Nakajima (Kanazawa University, Japan)
Guang-Uei Hung

Guang-Uei Hung

Chang Bing Show Chwan Memorial Hospital (Taiwan)

  1. Kaohsiung Medical University, MD, 1989-1998
  2. Residency, Department of Nuclear Medicine, Taichung Veterans General Hospital, 1998-2003
  3. National PET/Cyclotron Center, Taipei Vetetrans General Hospital, Taipei, Taiwan, 2000
  4. PET/CT program of UCLA Amhanson Biological Imaging Clinic, Los Angelos, USA, 2006
Professional Career (with duration)
  1. Associate Professor, Department of Nuclear Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 2020~current
  2. Associate Professor, Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, 2016-2020
  3. Member, Executive Committee, Society of Nuclear Medicne, Taiwan, ROC, 2014-2018
  4. Chair, Cardiology Committee, Society of Nuclear Medicne, Taiwan, ROC, 2014-2018
  5. Secretary General, Society of Nuclear Medicne, Taiwan, ROC, 2011-2014
Selected Publications in 5 years
  1. Hung GU, Ko KY, Lin CL, Yen RF, Kao CH. Impact of initial myocardial perfusion imaging versus invasive coronary angiography on outcomes in coronary artery disease: a nationwide cohort study. Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):567-574.
  2. Chen CC, Shen TY, Peterson CB, Hung GU, Pan T. Comparison of ejection fraction calculation between CT and SPECT at high heart rate: A dynamic cardiac phantom study. J Nucl Cardiol. 2021 Feb;28(1):311-316. (Co-Correspondence author)
  3. Hung GU, Zou J, He Z, Zhang X, Tsai SC, Wang CY, Chiang KF, Tang H, Garcia EV, Zhou W, Huang JL. Left-ventricular dyssynchrony in viable myocardium by myocardial perfusion SPECT is predictive of mechanical response to CRT. Ann Nucl Med. 2021 35(8):947-954.
  4. Wang CY, Hung GU, Lo HC, Tsai SC, He Z, Zhang X, Chiang KF, Zou J, Zhou W, Huang JL, Chen SA. Clinical impacts of scar reduction on gated myocardial perfusion SPECT after cardiac resynchronization therapy. J Nucl Cardiol. 2021 Aug 19. doi: 10.1007/s12350-021-02722-7. Online ahead of print. (Co-1st author)
Myocardial perfusion SPECT in advanced heart failure: focusing on the role of phase analysis
Summary of Speech
Since the invention of the phase analysis technique for ECG-gated myocardial perfusion SPECT (MPS) by Chen et al in 2005, it has led this imaging modality to discover a “New World” in nuclear cardiology. For patients with advanced heart failure, LV mechanical dyssynchrony by phase analysis of MPS provided a one-stop shop evaluation for selecting optimal candidates for CRT, guiding LV lead implantation of CRT at the latest activation site and avoiding scarred myocardium.
The degree and extent of myocardial ischemia/infarction demonstrated on myocardial perfusion SPECT had been shown the independent and powerful value for prognosis and risk stratification of ischemic heart disease, however, the perfusion information did not consistently predicted cardiac events for patients with advanced heart failure. Nevertheless, LV dyssynchrony by phase analysis was found to be the only significant variable over perfusion parameters, LVEF, EDV and ESV for predicting all-cause mortality.
For patients with advanced heart failure, one of the major challenges was to predict those who were at the highest risk for developing ventricular arrhythmia and sudden cardiac death (SCD), and selecting appropriate candidates for receiving implantable cardioverter defibrillators (ICD). It is encouraging that phase analysis of MPS has also been found useful for predicting appropriate ICD shocks and SCD events. Based on our study, myocardial scar burden, LVEF and LV dyssynchrony of MPS were significantly correlated to the development of ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) in CRT-treated patients. Incorporating findings of SPECT, ECG and echocardiography, our group further developed a risk factor-based model for predicting those patients at the highest risk of ventricular arrhythmia.
It has been more than a decade since phase analysis for MPS was invented, and nowadays this technique has already been added as a standard on all commercially available software for MPS. We recommend that LV dyssynchrony by phase analysis should be more widely used in the daily routine for optimizing the clinical patients care for those with advanced heart failure.
Nils Persson Johnson

Nils Persson Johnson

University of Texas, Houston (USA)

  • Bachelor of Science (B.Sc.), 2000
  • Physics and Computer Science (combined honors)
  • University of British Columbia
  • Vancouver, BC, Canada
  • Doctor of Medicine (M.D.), 2004
  • College of Physicians and Surgeons
  • Columbia University
  • New York (Manhattan), NY
  • Master of Science (M.S.), Epidemiology and Biostatistics, 2009
  • Department of Preventive Medicine Northwestern University Chicago, IL
  • Residency, Internal Medicine, 2004-2006 (research pathway)
  • Northwestern University McGaw Medical Center Chicago, IL
  • Fellowship, Cardiovascular Disease, 2006-2009
  • Northwestern University McGaw Medical Center Chicago, IL
  • Fellowship, Interventional Cardiology, 2009-2010
  • Northwestern University McGaw Medical Center Chicago, IL
  • Interventional Cardiology, August 2015 to July 2016
  • Heart and Vascular Center, Catharina Hospital Eindhoven, The Netherlands
  • Weatherhead Distinguished Chair of Heart Disease, 2015-Present Professor, 2021-Present
  • Associate Professor, 2014-2021
  • Assistant Professor, 2010-2014
  • Division of Cardiology, Department of Medicine
  • University of Texas Medical School at Houston Houston, TX
Associate Director, 2010-Present
  • Weatherhead P.E.T. Imaging Center
  • Memorial Hermann Hospital
  • University of Texas Medical School at Houston Houston, TX
  • Attending Physician, 2010-Present
  • Memorial Hermann Hospital – Texas Medical Center (TMC)
  • Off-shift Intensivist, 2008-2010
  • Resurrection Medical Center Chicago, IL
  • National Provider ID #1841484326
  • Illinois Medical License #036117931, 2007-2011
  • Texas Medical License #N5749, April 2010-present
  • DEA License #FJ0571035, October 2007-present
  • Diplomate in internal medicine, 2007-2017
  • Diplomate in cardiovascular disease, 2010-2030
  • Diplomate in interventional cardiology, 2011-2031
  • American Board of Internal Medicine (ABIM)
  • Certification Board of Nuclear Cardiology (CBNC), 2009-2030
  • AHA Advanced Cardiovascular Life Support (ACLS) until September 2022
  • Licentiate of the Medical Council of Canada (LMCC), 2006
  • Certification Board of Cardiovascular CT (CBCCT), 2009-2019
  • Diplomate, American Board of Clinical Lipidology (ABCL), 2013-2023
  • Elected as a Fellow of the ESC (F.E.S.C. designation), December 2016
  • European Society of Cardiology (ESC), 2016-Present National
  • Elected as a Fellow of the ACC (F.A.C.C. designation), February 2013
  • American College of Cardiology (ACC), 2006-Present
  • American Society of Nuclear Cardiology (ASNC), 2012-Present
Selected publications in 5 years
  1. Kitkungvan, D., Johnson, N.P., Roby, A.E., Patel, M.B., Kirkeeide, R., and Gould, K.L.: Routine Clinical Quantitative Rest Stress Myocardial Perfusion for Managing Coronary Artery Disease: Clinical Relevance of Test-Retest Variability. Journal of the American College of Cardiology (JACC): Cardiovascular Imaging. 10(5):565-577, 2017.
  2. Gargiulo, G., Stabile, E., Ferrone, M., Barbato, E., Zimmermann, F.M., Adjedj, J., Hennigan, B., Matsumura, M., Johnson, N.P., Fearon, W.F., Jeremias, A., Trimarco, B., and Esposito, G.; CONTRST Study Investigators. Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study. Cardiovascular Diabetology. 6(1):7, 2017.
  3. Kitkungvan, D., Lai, D., Zhu, H., Roby, A.E., Johnson, N.P., Steptoe, D.D., Patel, M.B., Kirkeeide, R., and Gould, K.L.: Optimal Adenosine Stress for Maximum Stress Perfusion, Coronary Flow Reserve, and Pixel Distribution of Coronary Flow Capacity by Kolmogorov-Smirnov Analysis. Circulation: Cardiovascular Imaging. 10(2). pii:e005650, 2017.
  4. Zimmermann, F.M., Pijls, N.H., De Bruyne, B., Bech, G.J., van Schaardenburgh, P., Kirkeeide, R.L., Gould, K.L., and Johnson, N.P.: What can intracoronary pressure measurements tell us about flow reserve? Pressure-Bounded coronary flow reserve and example application to the randomized DEFER trial. Catheterization and Cardiovascular Interventions. 33(7):991-7, 2017.
  5. Hennigan, B., Johnson, N., McClure, J., Corcoran, D., Watkins, S., Berry, C., and Oldroyd, K.G.: Validation of the "smart" minimum FFR Algorithm in an unselected all comer population of patients with intermediate coronary stenoses. International Journal of Cardiovascular Imaging. 33(7):991-7, 2017.
  6. Ahn, J.M., Zimmermann, F.M., Johnson, N.P., Shin, E.S., Koo, B.K., Lee, P.H., Park, D.W., Kang, S.J., Lee, S.W., Kim, Y.H., Lee, C.W., Park, S.W., Pijls, N.H.J., and Park, S.J.: Fractional flow reserve and pressure-bounded coronary flow reserve to predict outcomes in coronary artery disease. European Heart Journal. 38(25):1980-9, 2017.
  7. Eerdekens, R., Chavez, J.F., Fox, J.M., Flaherty, J.D., Dekker, L.R., and Johnson, N.P.: Predicting the infarct related artery in STEMI from the surface ECG:independent validation of proposed criteria. EuroIntervention. 13(8):953-61, 2017.
  8. Otterspoor, L.C., van Nunen, L.X., van 't Veer, M., Johnson, N.P., and Pijls, N.H.J.: Intracoronary Hypothermia Before Reperfusion to Reduce Reperfusion Injury in Acute Myocardial Infarction: A Novel Hypothesis and Technique. Therapeutic Hypothermia and Temperature Management. 7(4):199-205, 2017.
  9. Matsumura, M., Johnson, N.P., Fearon, W.F., Mintz, G.S., Stone, G.W., Oldroyd, K.G., De Bruyne, B., Pijls, N.H.J., Maehara, A., and Jeremias, A.: Accuracy of Fractional Flow Reserve Measurements in Clinical Practice: Observations From a Core Laboratory Analysis. Journal of the American College of Cardiology (JACC):Cardiovascular Interventions. 2017 Jul 24;10(14):1392-1401.
  10. Otterspoor L.C,. van 't Veer, M., van Nunen, L.X., Brueren, G.R.G., Tonino, P.A.L., Wijnbergen, I.F., Helmes, H., Zimmermann, F.M., van Hagen, E., Johnson, N.P., and Pijls, N.H.J.: Safety and feasibility of selective intracoronary hypothermia in acute myocardial infarction. EuroIntervention. 13(12):e1475-82, 2017.
  11. Nishi, T., Johnson, N.P., De Bruyne, B., Berry, C., Gould, K.L., Jeremias, A., Oldroyd, K.G., Kobayashi, Y., Choi, D.H., Pijls, N.H.J., Fearon, W.F.; and CONTRAST Study Investigators. Influence of Contrast Media Dose and Osmolality on the Diagnostic Performance of Contrast Fractional Flow Reserve. Circulation:Cardiovascular Interventions. 10(10). pii: e004985, 2017.
  12. Kobayashi, Y., Johnson, N.P., Zimmermann, F.M., Witt, N., Berry, C., Jeremias, A., Koo, B.K., Esposito, G., Rioufol, G., Park, S.J., Nishi, T., Choi, D.H., Oldroyd, K.G., Barbato, E., Pijls, N.H.J., De Bruyne, B., Fearon, W.F.; and CONTRAST Study Investigators. Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. Journal of the American College of Cardiology (JACC). 70(17):2105-13, 2017.
  13. Matsumura, M., Maehara, A., Johnson, N.P., Fearon, W.F., De Bruyne, B., Oldroyd, K.G., Pijls, N.H.J., Jenkins, P., Ali, Z.A., Mintz, G.S., Stone, G.W., and Jeremias, A.: Qualitative Resting Coronary Pressure Wave Form Analysis to Predict Fractional Flow Reserve. EuroIntervention. 14(15):e1601-e1608, 2019.
  14. Akosile, M., Zhu, H., Zhang, S., Johnson, N.P., Lai, DJ, and Zhu H.: Reassessing the Effectiveness of Right Heart Catheterization (RHC) in the Initial Care of Critically Ill Patients using Targeted Maximum Likelihood Estimation. International Journal of Clinical Biostatistics and Biometrics. 4(1):018, 2018.
  15. Johnson, N.P., Zelis, J.M., Tonino, P.A.L., Houthuizen, P., Bouwman, R.A., Brueren, G.R.G., Johnson, D.T., Koolen, J.J., Korsten, H.H.M., Wijnbergen, I.F., Zimmermann, F.M., Kirkeeide, R.L., Pijls, N.H.J., and Gould, K.L.: Pressure gradient vs. flow relationships to characterize the physiology of a severely stenotic aortic valve before and after transcatheter valve implantation. European Heart Journal. 39(28):2646-55, 2018.
  16. Svanerud, J., Ahn, J.M., Jeremias, A., van 't Veer, M., Gore, A., Maehara, A., Crowley, A., Pijls, N.H.J., De Bruyne, B., Johnson, N.P., Hennigan, B., Watkins, S., Berry, C., Oldroyd, K.G., Park, S.J., and Ali, Z.A.: Validation of a novel nonhyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 14(7):806-14, 2018.
  17. Fournier, S., Toth, G.G., De Bruyne, B., Johnson, N.P., Ciccarelli, G., Xaplanteris, P., Milkas, A., Strisciuglio, T., Bartunek, J., Vanderheyden, M., Wyffels, E., Casselman, F., Van Praet, F., Stockman, B., Degrieck, I., and Barbato, E.: Six-Year Follow-Up of Fractional Flow Reserve-Guided Versus Angiography-Guided Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions.11(6):e006368, 2018.
  18. Shah, S.V., Zimmermann, F.M., Johnson, N.P., Nishi, T., Kobayashi, Y., Witt, N., Berry, C., Jeremias, A., Koo, B.K., Esposito, G., Rioufol, G., Park, S.J., Oldroyd, K.G., Barbato, E., Pijls, N.H.J., De Bruyne, B., Fearon, W.F.; and CONTRAST Study Investigators. Sex Differences in Adenosine-Free Coronary Pressure Indexes: A CONTRAST Substudy. Journal of the American College of Cardiology (JACC):Cardiovascular Interventions. 11(15):1454-63, 2018.
  19. Gould, K.L., Johnson, N.P., Roby, A., Nguyen, T.T., Kirkeeide, R.L., Haynie, M., Lai, D., Zhu, H., Patel, M.B., Smalling, R.W., Arain, S., Balan, P., Nguyen, N.T., Estrera, A., Sdringola, S., Madjid, M., Nascimbene, A., Loyalka, P., Kar, B., Gregoric, I., Safi, H., and McPherson, D.: Regional Artery Specific Thresholds Of Quantitative Myocardial Perfusion By PET Associated With Reduced MI and Death After Revascularization In Stable CAD. Journal of Nuclear Medicine. 60(3):410-417, 2019.
  20. Zimmermann, F.M., Omerovic, E., Fournier, S., Kelbæk, H., Johnson, N.P., Rothenbühler, M., Xaplanteris, P., Abdel-Wahab, M., Barbato, E., Høfsten, D.E., Tonino, P.A.L., Boxma-de Klerk, B.M., Fearon, W.F., Køber, L., Smits, P.C., De Bruyne, B., Pijls, N.H.J., Jüni, P., and Engstrøm, T.: Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. European Heart Journal. 40(2):180-6, 2019.
  21. Dérimay, F., Johnson, N.P., Zimmermann, F.M., Adjedj, J., Witt, N., Hennigan, B., Koo, B.K., Barbato, E., Esposito, G., Trimarco, B., Rioufol, G., Park, S.J., Baptista, S.B., Chrysant, G.S., Leone, A.M., Jeremias, A., Berry, C., De Bruyne, B., Oldroyd, K.G., Pijls, N.H.J., and Fearon, W.F.: Predictive factors of discordance between the instantaneous wave-free ratio and fractional flow reserve. Catheterization and Cardiovascular Interventions. 94(3):356-363, 2019.
  22. Kitkungvan, D., Bui, L., Johnson, N.P., Patel, M.B., Roby, A.E., Vejpongsa, P.,Babar, A.K., Madjid, M., Nacimbene, A., Kumar, S., DeGolovine, A., and Gould, K.L.: Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity. European Heart Journal Cardiovascular Imaging. 20(7):751-762,2019.
  23. Johnson, N.P., Matsumura, M., Achenbach, S., Engstrom, T., Assali, A., Jeremias, A., Fournier, S., De Bruyne, B., Leon, M.B., and Fearon, W.F.: Angiography-Derived Fractional Flow Reserve Versus Invasive Nonhyperemic Pressure Ratios. Journal of the American College of Cardiology. 73(24):3232-3233, 2019.
  24. Johnson, N.P., Li, W., Chen, X., Hennigan, B., Watkins, S., Berry, C., Fearon, W.F., and Oldroyd, K.G.: Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio. European Heart Journal. 40(31):2585-2594, 2019.
  25. Balan, P., His, B., Thangam, M., Zhao, Y., Monlezun, D., Arain, S., Charitakis, K.,Dhoble, A., Johnson, N., Anderson, H.V., Persse, D., Warner, M., Ostermayer, D.,Prater, S., Wang, H., and Doshi, P.: The cardiac arrest survival score: A predictive algorithm for in-hospital mortality after out-of-hospital cardiac arrest. Resuscitation. 144:46-53, 2019.
  26. Wijntjens, G.W.M., van Uffelen, E.L., Echavarría-Pinto, M., Casadonte, L., Stegehuis, V.E., Murai, T., Marques, K.M.J., Yoon, M.H., Tahk, S.J., Casella, G., Leone, A.M., López Palop, R., Schlundt, C., Rivero, F., Petraco, R., Fearon, W.F., Johnson, N.P., Jeremias, A., Koo, B.K., Piek, J.J., and van de Hoef, T.P.: Individual Lesion-Level Meta-Analysis Comparing Various Doses of Intracoronary Bolus Injection of Adenosine With Intravenous Administration of Adenosine for Fractional Flow Reserve Assessment. Circulation: Cardiovascular Interventions. 13(1):e007893, 2020.
  27. Stegehuis, V.E., Wijntjens, G.W.M., van de Hoef, T.P., Casadonte, L., Kirkeeide, R.L., Siebes, M., Spaan, J.A.E., Gould, K.L., Johnson, N.P., and Piek, J.J.: Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect-combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial design. American Heart Journal. 222:139-146, 2020.
  28. Johnson, D.T., Fournier, S., Kirkeeide, R.L., De Bruyne, B., Gould, K.L., and Johnson, N.P.: Phasic pressure measurements for coronary and valvular interventions using fluid-filled catheters: Errors, automated correction, and clinical implications. Catheterization and Cardiovascular Interventions. 96(3):E268-E277,2020.
  29. Gould, K.L., Bui, L., Kitkungvan, D., Pan, T., Roby, A.E., Nguyen, T.T., and Johnson, N.P.: Pitfalls in quantitative myocardial PET perfusion I: Myocardial partial volumecorrection. Journal of Nuclear Cardiology. 27(2):386-396, 2020.
  30. Zelis, J.M., Tonino, P.A.L., Johnson, D.T., Balan, P., Brueren, G.R.G., Wijnbergen, I., Kirkeeide, R.L., Pijls, N.H.J., Gould, K.L., and Johnson, N.P.: Stress Aortic Valve Index (SAVI) with Dobutamine for Low-Gradient Aortic Stenosis: A Pilot Study, Structural Heart. 4(1):53-61, 2020.
  31. Zelis, J.M., Meiburg, R., Roijen, J.J.D., Janssens, K.L.P.M., van 't Veer, M., Pijls, N.H.J., Johnson, N.P., van de Vosse, F.N., Tonino, P.A.L., and Rutten, M.C.: 3Dprinted stenotic aortic valve model to simulate physiology before, during, and after transcatheter aortic valve implantation. International Journal of Cardiology. 313:32-34, 2020.
  32. Zelis, J.M., Zimmermann, F.M., Andriessen, F.P.J., Houthuizen, P., Van de Ven, J., Leuverman, J., Johnson, N.P., Pijls, N.H.J., Scharnhorst, V., Van 't Veer, M., and Tonino, P.A.L.: Assessment of exercise-induced changes in von Willebrand factor as a marker of severity of aortic stenosis. Open Heart. 7(1):e0011382, 2020.
  33. Murai, T., Stegehuis, V.E., van de Hoef, T.P., Wijntjens, G.W.M., Hoshino, M., Kanaji, Y., Sugiyama, T., Hamaya, R., Nijjer, S.S., de Waard, G.A., Echavarria-Pinto, M., Knaapen, P., Meuwissen, M., Davies, J.E., van Royen, N., Escaned, J., Siebes, M., Kirkeeide, R.L., Gould, K.L., Johnson, N.P., Piek, J.J., and Kakuta, T. Coronary Flow Capacity to Identify Stenosis Associated With Coronary Flow Improvement After Revascularization: A Combined Analysis From DEFINE FLOW and IDEAL. Journal of the American Heart Association. 9(14):e016130, 2020.
  34. Gould, K.L., Kitkungvan, D., Johnson, N.P., Nguyen, T., Kirkeeide, R., Bui, L., Patel, M.B., Roby, A.E., Madjid, M., Zhu, H., and Lai, D. Mortality Prediction by Quantitative PET Perfusion Expressed as Coronary Flow Capacity With and Without Revascularization. Journal of the American College of Cardiology (JACC):Cardiovascular Imaging.14(5):1020-1034, 2021.
  35. Kitkungvan, D., Johnson, N.P., Kirkeeide, R., Haynie, M., Carter, C., Patel, M.B., Bui, L., Madjid, M., Mendoza, P., Roby, A.E., Hood, S., Zhu, H., Lai, D., Sdringola, S., and Gould, K.L. Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). American Heart Journal. 237:135-146, 2021.
  36. Toth, G.G., Johnson, N.P., Wijns, W., Toth, B., Achim, A., Fournier, S., and Barbato, E. Revascularization decisions in patients with chronic coronary syndromes: Results of the second International Survey on Interventional Strategy (ISIS-2). International Journal of Cardiology. 336:38-44, 2021.
  37. Zimmermann, F.M., Mast, T.P., Johnson, N.P., Everts, I., Hennigan, B., Berry, C., Johnson, D.T., De Bruyne, B., Fearon, W.F., Oldroyd, K., Pijls, N.H.J., Tonino, P.A.L., and van 't Veer, M. Deep learning for prediction of fractional flow reservefrom resting coronary pressure curves. EuroIntervention. 17(1):51-58, 2021.
  38. Haeck, J.D.E., van 't Veer, M., Zimmermann, F.M., Neumann, F.J., Triantafyllis, A.S., Sjauw, K.D., Abdel-Wahab, M., Omerovic, E., Boxma-de Klerk, B.M., Pijls,N.H.J., Richardt, G., Tonino, P.A.L., Johnson, N.P., and Smits, P.C. Percutaneous Coronary Intervention vs Medical Therapy for Coronary Lesions With Positive Fractional Flow Reserve (FFR) but Preserved Pressure-Bounded Coronary Flow Reserve (CFR): A Substudy of the Randomized Compare-Acute Trial. Journal of Invasive Cardiology. 33(7):E557-E564, 2021.C.
Spectrum of myocardial perfusion: from infarct to normal and everything in between
Summary of Speech
Quantitative myocardial perfusion imaging allows us to measure absolute flow indexed to the amount of supplied muscle (cc/min/g). Over the past 15 years we have studied this entire spectrum in order to understand objective limits for distinguishing normal from abnormal. We began by imaging a cohort of normal people (not patients!) aged less than 40 with no risk factors. This group allowed us to understand truly normal perfusion, not accessible or measured invasively due to unethical risk of invasive catheterization for people. At the other end of the spectrum, low resting flows seen in transmural or nontransmural infarcts as verified by cardiac magnetic resonance imaging permit a boundary that identifies nonviable myocardium. Reduced stress flows imaged at the time of angina, ST-segment depression, and a relative perfusion defect indicate frank ischemia. Between normal flows and ischemia lies a wide continuum related to risk factor burden, anatomic atherosclerosis, clinical heart disease, and patients with previous revascularization procedures. Understanding the range of myocardial perfusion allows for an integrative characterization of coronary flow capacity, with its unique ability to predict prognosis and the impact of coronary revascularization.
Kenichi Nakajima

Kenichi Nakajima

Kanazawa University, Kanazawa (JAPAN)

Professional Career (with duration)
  • 1983 Department of Nuclear Medicine, Kanazawa University
  • 1987-88 Service Hospitalier Frédéric Joliot - Commissariat à l' énergie atomique, France
  • 1994 Kanazawa University Hospital
  • 2007 Kanazawa University; Associate Professor
  • 2010 Kanazawa University Hospital, Clinical Professor
  • 2019 Kanazawa University, Functional Imaging and Artificial Intelligence, Professor
Publications in 5 years
  • Nakajima K. Triglyceride deposit cardiomyovasculopathy: How to recognise a new disease entity. Heart 2021;107: 93-95
  • Saito S, Nakajima K, et al. Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging. EJNMMIRes 2021; 11: 105
  • Nakajima K, et al. Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. J Nucl Cardiol 2020 (Epub ahead of print)
  • Nakajima K, et al. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. Int J. Urol 2021; 28: 955-963
  • Nakajima K, et al. Risk stratification based on J-ACCESS risk models with myocardial perfusion imaging: Risk versus outcomes of patients with chronic kidney disease. J Nucl Cardiol 2020; 27: 41-50
  • Nakajima K, et al. Artificial neural network retrained to detect myocardial ischemia using a Japanese multicenter database. Ann Nucl Med 2018; 32; 303-310
  • Nakajima K, et al. Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure. Eur Heart J Cardiovasc Imaging. 2018; 19: 749-756
  • Nakajima K, et al. Diagnostic accuracy of an artificial neural network compared with statistical quantitation of myocardial perfusion images: a Japanese multicenter study. Eur J Nucl Med Mol Imaging. 2017; 44: 2280 – 2289
  • Nakajima K, et al. IQ•SPECT technology and its clinical applications using multicenter normal databases. Ann Nucl Med 2017; 31 (9): 649-659
Application of artificial intelligence / machine learning for nuclear cardiology in Japan
Summary of Speech
Artificial intelligence or machine learning has significant potential in data analysis and nuclear imaging; however clinical application is still limited as a reliable tool. As specialized knowledges and experience are needed in medicine and imaging diagnosis, the software programs prepared for such speciality fields will help nuclear medicine physicians, radiologists and cardiologists. One of the software programs available in Japan is “cardioREPO”, which used neural network for the detection of stress and rest defects and ischemia. The diagnostic accuracy was found to be comparable to experts as far as the existence of ischemia is concerned, while the final clinical decision will be a role of physicians. Prediction of mode of cardiac death using machine learning incorporating 123I-MIBG is also presented for chronic heart failure patients. The algorithm used 13 variables with MIBG and clinical backgrounds, and differential prediction of pump-failure death and sudden cardiac death/arrhythmic death might be done. Risk stratification integrating imaging-derived parameters and clinical backgrounds can be used for clinical decision making and potentially better compared with simple imaging diagnosis. Another application is segmentation of the organs to quantify tomographic imaging. The possible application of AI or machine learning will also be discussed.

Artificial neural network for MPI - Eur J Nucl Med Mol Imaging. 2017; 44: 2280 - 2289
MIBG to differentially predict modes of cardiac death - J Nucl Cardiol 2022; (Epub ahead of print: 2020 May 14)
CNN-based automatic heart segmentation for MIBG - EJNMMIRes 2021; 11: 105
Takahiro Higuchi

Takahiro Higuchi

Department of nuclear medicine and CHFC, University of Wuerzburg (Germany)

Education (with year of graduation)
  • 03/2002 PhD,Kanazawa University Graduate School, Japan
  • 03/1998 Medical school, Toyama University, Japan
Professional Career (with duration)
  • 09/2011 – present Professor of molecular imaging of the heart, Dept. of Nuclear Medicine, University Hospital Würzburg
  • 09/2007 – 08/2011 Research associate, Division of Nuclear medicine, Johns Hopkins Medical Institution
  • 09/2004 – 08/2007 Research fellow, Department of Nuclear Medicine, Technical University of Munich
  • 04/2002 – 08/2004 Medical Doctor, Kanazawa PET imaging Center
Publications in 5 years
  1. Immuno-metabolic interfaces in cardiac disease and failure. Bertero E, Dudek J, Cochain C, Delgobo M, Ramos G, Gerull B, Higuchi T, Vaeth M, Zernecke A, Frantz S, Hofmann U, Maack C. Cardiovasc Res. 2022 Jan 7;118(1):37-52.
  2. SPECT and PET Radiotracers in Renal Imaging.Werner RA, Pomper MG, Buck AK, Rowe SP, Higuchi T.Semin Nucl Med. 2022 Jan 17:S0001-2998(21)00104-5.
  3. Narrative review of generative adversarial networks in medical and molecular imaging.Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Ann Transl Med. 2021 May;9(9):821.
  4. The Number of Frames on ECG-Gated 18F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters.Eissler C, Werner RA, Arias-Loza P, Nose N, Chen X, Pomper MG, Rowe SP, Lapa C, Buck AK, Higuchi T. Mol Imaging. 2021 Dec 6;2021:4629459.
New horizon in cardiac molecular imaging
Summary of Speech
State of the art PET imaging technology provides high sensitivity for molecular detection, making it possible to sensitively monitor molecular alterations in the early stage of disease heart. The development of multiple tracers targeting specific biomarkers with excellent in vivo pharmacokinetic properties acerates allowance of accurate measurements of variety of important cardiac key markers, such as neurohumonal activity monitoring, myocardial metabolic activity and inflammation. In particular, due to physical and chemical key properties, F18 PET imaging agents allow for greater flexibility in imaging protocols and promising for routine clinical use compared to other radionuclides with shorter half- lives.

Oncology session

Sept. 7,2022 10:50-12:15

Subapriya Suppiah (University Putra Malaysia, Malaysia)
Kenji Hirata (Hokkaido University, Japan)
Prasanta Kumar Pradhan

Prasanta Kumar Pradhan

Sanjay Gandhi Post-graduate Institute of Medical sciences, Lucknow (India)

Education (with year of graduation)
  • High school Examination (H.S.E.) Board of Secondary Examination, Orissa India April 1978 First
  • Intermediate in Science (I.Sc.) Sambalpur University. April 1980 First
  • M.B.B.S. First V.S.S.Medical College Burla, India April 1983
  • M.B.B.S.Second V.S.S.Medical College Burla, India Oct 1984
  • M.B.B.S.Third V.S.S.Medical College Burla, India April 1985
  • M.B.B.S.Final V.S.S.Medical College Burla, India April 1986 Third Position In University
  • M.D. (Bio-Physics) All India Institute of Medical Sciences, New Delhi (India) June 1992 Passed
  • Diploma in Radiation Medicine (D.R.M.) Radiation Medicine Centre, BARC, Mumbai IndiaJuly 1994 Passed
  • Radiation Safety Officer (RSO) Bhabha Atomic Reseach Centre (BARC) Mumbai June 1994 Passed
  • Diploma in National Board (D.N.B.) National Board of Examination (NBE)New Delhi, India Nov 1995 Passed

**Licensure Holder of therapeutic license for administration of high dose radio-iodine therapy for treatment of thyroid cancer, MIBG,Lu-177 therapy for neuroendocrine and prostate cancer also

Professional Career (with duration)
  • Assistant Professor and Head in the Department of Nuclear Medicine, IGIMS, Patna from 18th Feb 1998 to 10th March 2000.
  • Assistant Professor in Department of Nuclear Medicine, SGPGIMS,Lucknow since 13th March 2000.to 30th June, 2004.
  • Associate Professor in Department of Nuclear Medicine, SGPGIMS, Lucknow from 1st July, 2004 to 30th June 2008.
  • Additional Professor in Department of Nuclear Medicine, SGPGIMS, Lucknow from 1st July, 2008 to 30th June 2012.
  • Presently working as Professor from 1st July 2012 to till Date
Publications in 5 years
  1. Ora M, Pradhan PK, Garg N, Kheruka S. Routine Stress-Rest Tc-99m MIBI Myocardial Perfusion Scintigraphy Underestimates Ischemia and Viability. Indian Journal of Clinical Cardiology. 2021;26324636211013680.
  2. Ora M, Nazar AH, Mishra P, Barai S, Arya A, Pradhan PK, et al. Factors predicting the risk of biochemical incomplete response in well-differentiated thyroid cancer after total thyroidectomy. Nuclear Medicine Communications. 2021;42(11):1187–94. (IF:1.46)
  3. Ora M, Nazar AH, Mishra P, Barai S, Arya A, Pradhan PK, et al. Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: a retrospective study. Thyroid Research. 2021;14(1):1–10. (IF:2.52)
  4. Vikram Sharanappa, Raouef Ahmed Bichoo,Anjali Mishra,Prasanta Kumar Pradhan, Saroj Kanta Mishra. Circumferential Laryngotracheal Resection in Thyroid Cancer: Experience and Outcome in a Single Center. Indian J Otolaryngol Head Neck Surg (IF:0.42) https://doi.org/10.1007/s12070-020-02339-1
  5. Cutler CS, Bailey EA, Kumar V, Sally W,Schwarz, Henry Hee-Seung Bom, Jun Hatazawa, Diana Paez, Pilar Orellana, Lizette Louw, Fernando Mut, Hiroki Kato, Arturo Chiti, Savvas Frangos, Frederic H Fahey, Gary Dillehay, Seoung Jun Oh, Dong Soo Lee, Sze Ting Lee, Rodolfo Nunez-Miller, Gurupad Bandopadhyaya, Prasanta Pradhan and Andrew M Scott. Global issues of radiopharmaceutical access and availability: a nuclear medicine global initiative project. J Nucl Med. 2020;61(8) (IF:5.83)
  6. Ora M, Nazar AH,Pradhan PK, Mishra P, Barai S, Arya A, Gambhir S. The utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and possible role of a limited regional scan. Indian J Nucl Med 2020;35:203-9 (IF:0.171)
  7. Jha, C.K., Mishra, A., Pradhan PK, Gambhir S, Agarwal G, Agarwal A, Chand Gyan, Mishra SK. Outcome of 18f-Fluorodeoxyglucose Positron Emission Tomography (PET)-Directed Resections in Differentiated Thyroid Carcinoma (DTC): Experience in a Developing Country. Indian J Surg Oncol (2020). https://doi.org/10.1007/s13193-020-01087-6 (IF:0.610)
  8. Lokeshwaran Madurai Kalimuthu, Vivek Kumar Saini, Prasanta Kumar Pradhan Lymphoscintigraphy In a Case of Recurrent Chylopericardium. Asia Oceania J Nucl Med Biol. 2020 Spring; 8(2): 157–159
  9. Kalimuthu LM, Nazar AH,Pradhan PK. Idiopathic hepatic and splenic uptake of 99mTc-methylene diphosphonate. Indian J Nucl Med 2020;35:238-40.(IF:0.171)
  10. Jun Hatazawa MD, PhD*Durre Sabih MD, PhD †YamingLi MD, PhD‡ Prasanta Kumar Pradhan MD§ DianaPaez MD||.Nuclear Cardiology in Asia. Seminars in Nuclear Medicine, May 2020:50(3);270-279 (IF:5.83)
  11. Yadav S.K., Jha C.K., Patil S., Datta D., Mishra A., Pradhan P.K. Lutetium therapy-induced carcinoid crisis: A case report and review of literature. J. Can. Res. Ther. 2020 doi: 10.4103/jcrt.JCRT_22_18.(1.326)
  12. Dhingra VK, Pradhan PK, Garg N, Basu S. The feasibility and safety of graded adenosine stress test for myocardial perfusion in asthmatic and/or COPD patients.Hell J Nucl Med. 2019 May-Aug;22(2):135-139.(IF:0.982)
Recent advances in management of radioiodine refractory thyroid (RAIR) cancer
Summary of Speech
The objective of this lecture is to enumerate different available approaches for management of refractory thyroid cancer and its advances in recent past.
DTC are slowly progressive tumors with good prognosis with survival of 20 years or more in 90% of patients with conventional treatment i.e with total thyroidectomy with locoregional lymphnode clearance,radioiodine therapy and suppressive thyroid hormone.However, a subgroup of patients with DTC develops recurrent and metastatic disease and is refractory to radiodine therapy and showing decreased survival.
Management of RAIR thyroid cancer patients as per ATA diagnostic criteria will be dealt as per recent guideline and their investigative algorithm and treatment. Current therapy provided in the field is far from ideal with various approaches.Molecular functional imaging was used as a method of metastatic lesion characterization for sub-classification of patients and treat each sub group differently forming the basis for a variety of individualized treatment regimens.
The newer ways of molecular imaging, treatment and follow up care will be discussed with respect to redifferentiation therapy, tyrosine kinase inhibitors, possible radioisotopic therapy and combinatorial therapy.
RAIR thyroid cancer patients need regular monitoring in view of recurrence and progression through the emergence of new mutations in the cancer cells. Its expected that these therapeutic options can provide longer progression free interval (PFS) with less morbidity.
Qaisar Hussain Siraj

Qaisar Hussain Siraj

Department of Nuclear Medicine, Farwaniya Hospital (Kuwait)

Dr Qaisar Siraj is a Senior Consultant in Nuclear Medicine and PET/CT at the Farwaniya Hospital in Kuwait. He graduated from Dow Medical College, the University of Karachi, in 1977 and later gained his Master’s and Doctorate in Nuclear Medicine from the Royal Free Hospital School of Medicine, University of London (1984 and 1993). He has worked in the speciality of Nuclear Medicine for 38 years (including 32 years at the consultant level). His experience includes ten years as Lead Clinician in Nuclear Medicine with the Portsmouth Hospitals NHS Trust (UK) as the Lead Clinician and Head of the nuclear medicine departments at the Royal Hospital Haslar, St. Mary’s and Queen Alexandra hospitals in Portsmouth. He has worked in many other prestigious NHS hospitals in the UK and at a consultant level abroad. Dr Siraj is a Founder Examiner for the Asian Nuclear Medicine Board and an IAEA expert in nuclear medicine and has worked on the certification and quality panels of the General Medical Council, UK. He is the Editor-in-Chief of the World Journal of Nuclear Medicine and the Founding Editor of the Pakistan Journal of Nuclear Medicine. He is the author of numerous refereed journal publications.
Dual tracer radionuclide imaging in hyperparathyroidism: thallium-201 parathyroid scintigraphy revisited
Summary of Speech
Objectives: 99mTc-sestamibi is the current radiopharmaceutical of choice for the localization of hyperactive lesions of the parathyroid glands in patients with hyperparathyroidism. However, there are multiple factors that adversely affect the accumulation and retention 99mTc-sestamibi in the hyperfunctioning parathyroid tissue, resulting in a false-negative scan. The objective of this study was to investigate the possibility of an incremental diagnostic role of thallium-201 parathyroid scintigraphy in patients with presumably false-negative 99mTc-sestamibi scan results.
Patients and methods: The study comprised of 22 patients (16 with primary hyperparathyroidism and 6 with secondary hyperparathyroidism) where 99mTc-sestambi scan was initially negative, inconclusive or where additional lesions were suspected on the SPECT/CT scan with the CT component identifying lesion(s) without significant 99mTc-sestamibi uptake.
Results: The results of our study show that in 22 patients (5 males, 17 females; age range 26-81; median age 53.4) further imaging with thallium-201 SPECT/CT scan showed 46.5% additional lesions in patients with hyperparathyroidism caused by an adenomatous or hyperplastic parathyroid lesion. In patients with primary hyperparathyroidism caused by an adenomatous or hyperplastic parathyroid lesion, further imaging with thallium-201 showed 59% additional hyperactive parathyroid lesions. In patients with secondary hyperparathyroidism further imaging with thallium-201 SPECT/CT showed additional 33.3% hyperplastic parathyroid lesions.
Conclusion: The results of this pilot study strongly advocate a role for thallium parathyroid SPECT/CT imaging in patients with primary and secondary hyperparathyroidism where the initial 99mTc-sestamibi scan is deemed to be false-negative in the presence of biochemical hyperparathyroidism.

Keywords: Hyperparathyroidism, parathyroid hyperplasia, parathyroid adenoma, 99mTc-sestamibi, 201Tl-thallous chloride, SPECT/CT
Xiao-Feng Li

Xiao-Feng Li

Department of Nuclear Medicine, Shenzhen People’s Hospital, Shenzhen (China)

Education (with year of graduation)
  • Bachelor of Medicine (M.B.) Norman Bethune University of Medical Sciences (Changchun, China) 1993
  • Ph.D. in medical sciences with honor, Kanazawa University (Kanazawa, Japan) 2003
  • Doctor of Medicine (M.D.) The University of the State of New York (Albany NY, USA) 2018
  • Fellow, Memorial Sloan-Kettering Cancer Center, New York NY, USA 2009
Professional Career (with duration)
  • 1993-1998 Assistant Professor & assistant attending, Department of Nuclear Medicine, The Second Affiliated Hospital of Harbin Medical University (Harbin China)
  • 1998-2003 Teaching and research assistant, Kanazawa University (kanazawa Japan)
  • 2003-2008 Research fellow, Memorial Sloan-Kettering Cancer Center (New York NY)
  • 2008-2009 Research associate, Memorial Sloan-Kettering Cancer Center (New York NY)
  • 2009-2017 From Assistant professor to clinical professor, Department of Radiology University of Louisville (Louisville KY)
  • 2017-2018 Chairman and chief attending, Department of Nuclear Medicine, Shenzhen Hospital of Southern Medical University (Shenzhen China)
  • 2018-current Chairman and chief attending, Department of Nuclear Medicine, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, and The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China
Publications in 5 years
  1. Li J, Zhang G, Wang X and Li XF*. Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? Future Oncology. 2015 May;11(10):1531-41
  2. Cui YL, Wang X, Li XF*. (18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer. Future Oncol. 2015;11(20):2841-9. doi: 10.2217/fon.15.205. Epub 2015 Sep 11. PubMed PMID: 26361064.
  3. Zhang Q, Du Y, Jing L, Liang X, Li Y, Jia X, Li XF, Dai Z and Tian J. IRDye-800CW Conjugated Endostar-loaded PLA Nanoparticles Operate as a Novel Theranostic Nanomedicine for Breast Cancer. Journal of biomedical nanotechnology 2016 Mar;12(3):491-502
  4. Russell J, Tian J, Kinuya S, Shen B and Li XF*. Editorial: Molecular imaging plays critical role for personalized medicine. BioMed Research Int. 2016 June; 2016:5170159. doi: 10.1155/2016/5170159. Epub 2016 Aug 29
  5. Wu Y, Zhang G, Wang X, Zhao Z, Wang T, Wang X and Li XF*. Early detection of rheumatoid arthritis in rats and humans with 99mTc-3PRGD2 scintigraphy: Imaging synovial neoangiogenesis. Oncotarget. 2017;8:5753-5760.
  6. Wang X, He Y, Zhou W, Bai X, Wang X, Wu Y, and Li XF. Mismatched Intratumoral Distribution of 18F-Fluorodeoxyglucose and 3'-Deoxy-3'-18F-Fluorothymidine in Lung Cancer of Patients. Oncology Letters 2017;14:5279-5284.
  7. Li Y, Wang Q, Wang X, Li X, Wu H, Wang Q, Yao Z, Miao W, Zhu X, Hua F, Zhang X, Cheng C, Zhang W, Hou Q, Li Y, and Li XF. Expert Consensus on clinical application of FDG PET/CT in infection and inflammation. ANN NUCL MED. 2020 May;34(5):369-376.
  8. Li Y, Zhao L and Li XF*. The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy. FRONTIERS IN PHARMACOLOGY 2021 Apr 19;12:636892. doi: 10.3389/fphar.2021.636892. eCollection 2021.
  9. Yao Y, Li YM, He ZX, Civelek AC and Li XF*. Likely Common Role of Hypoxia in Driving 18F-FDG Uptake in Cancer, Myocardial Ischemia, Inflammation and Infection, Cancer Biotherapy & Radiopharmaceuticals 2021 Oct;36(8):624-631
  10. Li Y, Zhao L, Li XF* Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. doi: 10.1177/15330338211036304.
  11. Li Y, Zhao L, Li XF*. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy. Front Oncol. 2021 Jul 29;11:700407. doi: 10.3389/fonc.2021.700407. eCollection 2021.
Revisiting Preclinical and Clinical Application of 18F-FDG PET in Solid Malignancies: Likely Role of Hypoxia
Summary of Speech
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography has become an important tool for detection, staging and management of many types of cancer. Pasteur effect, Warburg effect and reverse Warburg effect have been used to explain glucose metabolism in cancer. In animal models of cancer, we have demonstrated that 18F-FDG avidly accumulates in poorly proliferating and hypoxic cancer cells, but low in well perfused (and proliferating) cancer cells, stroma and necrosis, therefore,18F-FDG is hypoxia-avid PET tracer, not a cancer-specific tracer (J Nucl Med 2010;51:632-8,J Nucl Med 2012; 53:1262–1268, Translational Oncology 2014;7:240-247,J Nucl Med 2015; 56:607–612). 18F-FDG PET routinely uses on oncology; 95% solid malignancy presents hypoxia. We have explored that increased 18F-FDG uptake in ischemic myocardium, infection/inflammation would also be explained by the presence of hypoxia (Cancer Biother Radiopharm. 2021;36:624-631), which explains why 18F-FDG-avid infection/inflammation and malignancies are sometimes difficult to be distinguished clinically, on the other hand, some cancer are non-18F-FDG-avid to be visualized by PET alone, such as, those malignancies have not presented hypoxia. Clinically we have demonstrated the pattern “exclusion of blood perfusion and glucose metabolism in a pilot dual-phase 18F-FDG PET patients study, and concluded intratumoral 18F-FDG accumulation and 18F-FDG “vascular-nuclear-graphy” are mutually exclusive in patients with lung cancer (OncoTarget 2017;27;8:43536-43542) and HCC (SNMMI 2019). In conclusion, 18F-FDG18F-FDG highly accumulation in hypoxic and poorly proliferating cancer cells, 18F-FDG is not a cancer specific PET tracer. Revisiting18F-FDG uptake mechanism may promote cancer care.

Theranostics session

Sept. 7,2022 13:30-15:00

Mohamad B Haidar (American University of Beirut Medical Center, Lebanon)
Tadashi Watabe (Osaka University, Japan)
Rudolf Werner

Rudolf Werner

University Hospital Würzburg, Department of Nuclear Medicine (Germany)
Johns Hopkins School of Medicine, Baltimore, MD (USA)

Academic Education
  • 2006 – 2013 University of Wuerzburg, Subinternship Zürich (Switzerland), Medicine
Scientific Qualifications
  • Doctoral Thesis, Dr. med.; University of Wuerzburg, Department of Internal Medicine, Cardiology, 2013; Supervisor: Professor Dr. W. Voelker
  • Habilitation, Venia Legendi "Experimental Nuclear Medicine", Medical School Hannover, Department of Nuclear Medicine, 2020; Supervisor: Professor Dr. F. M. Bengel
  • Habilitation ("Umhabilitation"), Venia Legendi "Nuclear Medicine", University Hospital Würzburg, Department of Nuclear Medicine, 2021; Supervisor: Professor Dr. A. K. Buck
Postgraduate Positions
  • 2022, ongoing Adjunct Assistant Professor, Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD (Head: Dr. M. G. Pomper)
  • 2021, ongoing Vice Head, Department of Nuclear Medicine, University Hospital Wuerzburg, Germany (Head: Professor Dr. A. K. Buck)
  • 2020 Board Certification Nuclear Medicine
  • 2019 - 2020 Residency/Fellowship Department of Nuclear Medicine, Medical School Hannover, Germany (Head: Professor Dr. F. M. Bengel)
  • 2017 - 2018 Post-Doctoral Fellowship, Johns Hopkins School of Medicine, Division of Nuclear Medicine, Baltimore, MD (Head: Dr. M. G. Pomper)
  • 2013 - 2018 Residency/Fellowship Department of Nuclear Medicine, University Hospital Wuerzburg, Germany (Head: Professor Dr. A. K. Buck)
  • 2016 Winning Moderated Poster, European Society of Cardiology
  • 2017 Young Investigator Award, Cardiovascular Track, Society of Nuclear Medicine
  • 2018 Marc-Tetalman Award, Society of Nuclear Medicine
  • 2018 Dagmar-Eißner Award, Mittelrheinische Gesellschaft für Nuklearmedizin
  • 2019 – 2020 Clinician Scientist Program PRACTIS, Medical School Hannover
Selected Extramural Funding
  • 2022 German Research Foundation: CRC1525 "Cardio-Immune Interfaces" (PI)
  • 2020 Internal HiLF Funding, Hannover Medical School (PI)
Selected Publications
  1. Buck AK*, Haug A*, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE*, Werner RA*. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using 68Ga-Pentixafor PET. J Nucl Med, 2022, Mar.
  2. Werner RA*, Koenig T*, Diekmann J, Haghikia A, Derlin T, Thackeray JT, Napp C, Wester HJ, Ross TL, Schaefer A, Bauersachs J, Bengel FM. CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation: Prognostic Value after Reperfused Myocardial Infarction. JACC Cardiovasc Imaging. 2021 Oct 7;S1936-878X(21)00641-0.
  3. Werner RA, Hess A, Koenig T, Diekmann J, Derlin T, Melk A, Thackeray JT, Bauersachs J, Bengel FM. Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. Theranostics. 2021, May, doi: 10.7150/thno.61423.
  4. Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging. J Nucl Med. 2018, Dec;59(12):1857-1864.
  5. Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping after Endoradiotherapy with 177Lu-DOTATATE/-TOC by One Single Measurement after four Days. J Nucl Med. 2018 Jan;59(1):75-81.
  6. Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for neuroendocrine tumors in the late 2010s – where do we stand, where do we go? Theranostics. 2018, Nov 29;8(22):6088-6100.
  7. Werner RA*, Koshino K*, Arimitsu K*, Lapa C, Javadi MS, Rowe SP, Nose N, Kimura H, Fukushima K, Higuchi T. Stability of Distribution of F18 Flurpiridaz After Transient Coronary Occlusion in Pigs. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2269-2271.
  8. Werner RA, Wakabayashi H, Bauer J, Schütz C, Zechmeister C, Hayakawa N, Javadi MS, Lapa C, Jahns R, Ergün S*, Jahns V*, Higuchi T*. Longitudinal 18F-FDG PET imaging in a rat model of autoimmune myocarditis. Eur Heart J Cardiovasc Imaging. 2019;20:467-474.
  9. Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S, Javadi M, Schwaiger M, Nekolla SG, Higuchi T. Retention Kinetics of the 18F-labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with 11C-HED and 123I-MIBG. J Nucl Med. 2015;Sep 56(9):1429-33.
  10. Werner RA, Thackeray JT, Diekmann J, Weiberg D, Bauersachs J, Bengel FM. The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care towards Molecular Medicine. J Nucl Med. 2020, Jul; 61:951-961.

(*) shared authorship.

Emerging Theranostics for Cancer
Summary of Speech
Recent years have witnessed an expanded use of the theranostic concept, including prostate specific membrane antigen (PSMA) for treatment of prostate cancer and somatostatin receptor-targeted concepts for neuroendocrine neoplasms. Beyond those established theranostic strategies, novel targets are currently emerging, e.g., the C-X-C motif chemokine receptor 4 (CXCR4). The CXCR4-directed PET radiotracer [68Ga]PentixaFor has already demonstrated excellent read-out capabilities for solid tumors, such as adrenocortical carcinoma or for hematological malignancies, including multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. In a theranostic approach, CXCR4-directed endoradiotherapies using the theranostic equivalent [177Lu]/[90Y]PentixaTher achieved sufficient bone marrow ablation for subsequent conditioning therapies and stem cell transplantation. This talk will give an overview of this currently emerging target and will introduce the CXCR4-directed theranostic concept for a large variety of solid cancers and hematological neoplasms.
Xie Wanying

Xie Wanying

Dept of Nuclear Medicine and Molecular Imaging, Singapore General Hospital (Singapore)

Education (with year of graduation)

I graduated with a bachelor in Medicine and surgery from National University of Singapore in 2005. Subsequently, I obtained entrance to the Royal College of Radiologists in 2011 and trained as a nuclear medicine physician; and also obtained master of medicine in Diagnostic Radiology (Singapore). I have a special interest in the use of diagnostic nuclear medicine imaging for oncology and neuroimaging.

In 2013, I received the HMDP award for PET-MRI and PET-CT imaging to both UCLH and Royal Marsden Hospital (London), looking specifically at novel radiotracers in oncoIogy and the use of PET-MRI in research. I currently work at the department of Nuclear Medicine and PET in Singapore General Hospital.

Professional Career (with duration)

Adjunct Assistant Professor at Duke NUS from 2017- Current Senior Consultant at Singapore General Hospital (Nuclear Medicine and Molecular Imaging) from 2014 to Current

Publications in 5 years
  1. Stephanei M, Sue-Ann Ng; Wang YT; Xie WY; David C Ng; Andrea H.L. Low. PET-MRI with T1 MOLLI mapping to detect systemic sclerosis bowel inflammation and fibrosis European Journal of Radiology 2018 June (Article; Published in print)
  2. Simon KST, C.Chen, Shahul Hameed, A Ng, N Kandiah, Kumar M Prakash, Xie WY, Winnie WC Lam, Gwen LS, LL Chan, Pedro Rosa-Neto, Serge Gauthier, Kok Pin Ng. Phantom bedside intruder in Parkinson’s disease Neurology and Clinical Neuroscience 2018 Nov 25 (Article; Published in Print)
  3. Huang HL, AKT Tong, Thang SP, Sean YX, Winnie WC Lam, Kelvin SH Loke, Charlene YL Tang, Lenith Tai JC, Gideon SK Ooi, Low HC, Butch M Magsombol, Tham WY, Charles XY Goh, Colin JX Ta, Khor YM, Sumbul Zaheer, Pushan Bharadwaj, Xie WY, David CE Ng. Current Status and Growth of Nuclear Theranostics in Singapore Nuclear Medicine and Molecular Imaging
  4. Kalimuddin S, Xie W, Watanabe S, Tham JY, Sam H, Chan KWK, Yap TS, Totman JJ, Chacko AM, Vasudevan SG, Low JG. 18F-fluorodeoxyglucose positron emission tomography as a window into human dengue pathophysiology. Antiviral Res. 2020 Dec 3;185:104991. doi: 10.1016/j.antiviral.2020.104991. Epub ahead of print. PMID: 33279522.
  5. Tan Si Qi, Adeline Ngoh Seow Fen, Ng Wai Hoe, Xie Wanying, Janardhan Krishnappa, Nazima Binte Sahul Hamed, Tang Phua Hwee, Tchoyoson Lim Choie Cheio, Kenneth Chang Tou En, Lee Ming, Martha Kao I-Ming, David Low Chyi Yeu, Derrick Chan Wei Shih. Evaluation and outcomes of paediatric epilepsy surgery in Singapore: a single-centre audit
PSMA therapy: Now and What’s Next?
Summary of Speech
Prostate cancer is a one of the commonest cancer worldwide, and a leading cause of cancer in males. Patients presenting with metastatic prostate cancer tend to have poorer outcomes, with overall survival of less than 5 years. Most patients on androgen deprivation therapy eventually progress to castration resistant metastatic prostate cancer. These patients have dismal survival rates, with overall survival of less than 3 years, despite several life prolonging therapies. Prostate-specific membrane antigen (PSMA) is over- expressed in prostate cancer cells, with higher expression in higher-grade and metastatic castration-resistant disease. PSMA imaging has been widely accepted in imaging of prostate carcinoma. Radionuclide therapy targeting the PSMA receptor has been increasingly used in many countries. PSMA therapy has a wide safety profile and favorable results have been reported in the TheraP and VISION trials. FDA approval for PSMA therapy has recently been obtained in March 2022. In this presentation, we will summarize the highlights of the TheraP and VISION trials and share the results of our local experience with PSMA therapy.
Dale L Bailey

Dale L Bailey

Royal North Shore Hospital, Sydney (Australia)

Education (with year of graduation)
  • PhD – University of Surrey (1996)
  • MAppSc – UTS (1986)
  • BAppSc – UTS (1983)
Professional Career (with duration)
  • 2019-2021 Director, Sydney Vital Translational Cancer Research Centre (CINSW) (Part-time)
  • 2010-present Professor, Discipline of Medical Imaging Sciences, University of Sydney (Part-time)
  • 2010-2019 Hon. Affiliate, Faculty of Medicine & Health (Northern Clinical School), University of Sydney
  • 2010-present Hon. Affiliate, School of Physics, University of Sydney
  • 2006-2009 Associate Professor, Discipline of Medical Radiation Sciences, University of Sydney (Part-time)
  • 2006-2009 Honorary Associate, School of Physics, Faculty of Science, University of Sydney
  • 2003-2009 Clinical Associate Professor, Faculty of Medicine (Northern Clinical School), University of Sydney
  • 2003-2006 Senior Lecturer in Physics, School of Medical Radiation Sciences, University of Sydney (Part-time)
  • 2002-present Principal Medical Physics Specialist, Dept of Nuclear Medicine, Royal North Shore Hospital, Sydney
  • 2001-2005 "Recognised Teacher" in Medicine, King’s College London
  • 2000-2002 Honorary Senior Lecturer in Radiological Sciences, King’s College, London
  • 1999-2002 Consultant Physicist-in-Charge, Department of Nuclear Medicine, Guy’s & St Thomas’ Hospital, London
  • 1997-2000 Honorary Lecturer in Radiological Sciences, United Medical & Dental Schools, London
  • 1994-1999 Senior Non-Clinical Scientist (Physics), MRC Cyclotron Unit, Hammersmith Hospital, London
  • 1989-91 Visiting Colleague, MRC Cyclotron Unit, Hammersmith Hospital, London
  • 1983-93 Scientific Officer (Physics), Dept of Nuclear Medicine, Royal Prince Alfred Hospital, Sydney
  • 1983 Visiting Lecturer in Radiology, Harvard Medical School, Boston, USA
  • 1981 Trainee Physicist, Australian Atomic Energy Commission, Sydney
Publications in 5 years
  1. Fearn NR, Dylke ES, Bailey D, Kilbreath SL. Lymphoscintigraphy as an Outcome Measurement for Conservative Upper Limb Lymphedema Treatments: A Systematic Review. Lymphat Res Biol. 2021/11/09 ed (2021)
  2. Chan D, Ulaner G, Pattison D, Wyld D, Ladwa R, Kirchner J, Li B, Lai WV, Pavlakis N, Roach P, Bailey DL. Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker. Journal of Nuclear Medicine:jnumed.120.257659-undefined (2021)
  3. Sabanathan D, Campbell DH, Velonas VM, Wissmueller S, Mazure H, Trifunovic M, Poursoltan P, Ho-Shon K, Mackay TR, Lund ME, Lu Y, Roach PJ, Bailey DL, Walsh BJ, Gillatt D, Gurney H. Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers. Asia Oceania Journal of Nuclear Medicine and Biology:- (2021)
  4. Chan DL, Clarke SJ, Engel A, Diakos CI, Pavlakis N, Roach PJ, Bailey DL, Bauer J, Findlay M. Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). Eur J Clin Nutr. 2021/05/15 ed (2021)
  5. Beyer T, Bailey DL, Birk UJ, Buvat I, Catana C, Cheng Z, Fang Q, Giove F, Kuntner C, Laistler E, Moscato F, Nekolla SG, Rausch I, Ronen I, Saarakkala S, Thielemans K, van Elmpt W, Moser E. Medical Physics and Imaging–A Timely Perspective. Frontiers in Physics 9 (2021)
  6. Francis R, Bailey DL, Hofman MS, Scott A. The Australasian Radiopharmaceutical Trials Network (ARTnet) - Clinical Trials, Evidence and Opportunity. J Nucl Med 62. 2021/01/02 ed:755-756 (2020)
  7. Meikle SR, Sossi V, Roncali E, Cherry SR, Banati R, Mankoff D, Jones T, James M, Sutcliffe J, Ouyang J, Petibon Y, Ma C, El Fakhri G, Surti S, Karp JS, Badawi RD, Yamaya T, Akamatsu G, Schramm G, Rezaei A, Nuyts J, Fulton R, Kyme A, Lois C, Sari H, Price J, Boellaard R, Jeraj R, Bailey DL, Eslick E, Willowson KP, Dutta J. Quantitative PET in the 2020s: a roadmap. Physics in Medicine & Biology 66: IOP Publishing:06RM01 (2021)
  8. Marquis H, Deidda D, Gillman A, Willowson KP, Gholami Y, Hioki T, Eslick E, Thielemans K, Bailey DL. Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry. EJNMMI Physics 8:16 (2021)
  9. Hioki T, Gholami YH, McKelvey KJ, Aslani A, Marquis H, Eslick EM, Willowson KP, Howell VM, Bailey DL. Overlooked potential of positrons in cancer therapy. Sci Rep 11. 2021/01/30 ed:2475 (2021)
  10. Bailey DL, Sabanathan D, Aslani A, Campbell DH, Walsh B, Lengkeek NA. RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics. Asia Oceania Journal of Nuclear Medicine and Biology 9:1-8 (2021)
  11. Currie GM, Bailey DL. A Technical Overview of Technegas as a Lung Ventilation Agent. Journal of Nuclear Medicine Technology:jnmt.121.262887 (2021)
  1. Bailey DL, Philips W, Baldock C. Topical Debate: The future of radiotherapy is molecular. Phys Eng Sci Med 43. 2020/08/18 ed:755-759 (2020)
  2. Willowson KP, Schembri GP, Bernard EJ, Chan DL, Bailey DL. Quantifying the effects of absorbed dose from radioembolisation on healthy liver function with [(99m)Tc]TcMebrofenin. Eur J Nucl Med Mol Imag 47. 2020/01/21 ed:838-848 (2020)
  3. Bailey DL, Roach PJ. A Brief History of Lung Ventilation and Perfusion Imaging Over the 50-Year Tenure of the Editors of Seminars in Nuclear Medicine. Semin Nucl Med 50. 2019/12/18 ed:75-86 (2020)
  4. Rutting S, Mahadev S, Tonga KO, Bailey DL, Dame Carroll JR, Farrow CE, Thamrin C, Chapman DG, King GG. Obesity alters the topographical distribution of ventilation and the regional response to bronchoconstriction. J Appl Physiol (1985) 128. 2019/11/22 ed:168-177 (2020)
  5. Chan DL, Hoang J, Roach PJ, Arena J, Bailey DL, Nevell D, Pavlakis N, Engel A, Bernard EJ. Routine Early 68Ga-DOTATATE Positron Emission Tomography Has Low Yield After Resection of Appendiceal Neuroendocrine Neoplasms. Pancreas 49. 2020/07/14 ed:891-896 (2020)
  6. Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, Davis A, Bailey DL, Pavlakis N, Cehic G, Macdonald W, Wyld D, Segelov E. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. Oncotarget 11. 2020/07/18 ed:2636-2646 (2020)
  7. Chan DL, Bernard EJ, Schembri G, Roach PJ, Johnson M, Pavlakis N, Clarke S, Bailey DL. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. Neuroendocrinology 110. 2019/11/12 ed:950-958 (2020)
  1. Bailey DL, Farrow CE, Lau EM. V/Q SPECT-Normal Values for Lobar Function and Comparison with CT Volumes. Semin Nucl Med 49. 2018/12/14 ed:58-61 (2019)
  2. Bailey DL, Roach PJ. Letter From the Guest Editors. Semin Nucl Med 49. 2018/12/14 ed:2-3 (2019)
  3. Sammel AM, Hsiao E, Schembri G, Nguyen K, Brewer J, Schrieber L, Janssen B, Youssef P, Fraser CL, Bailey E, Bailey DL, Roach P, Laurent R. Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Chest for Giant Cell Arteritis: The Double-Blinded Giant Cell Arteritis and PET Scan (GAPS) Study. Arthritis Rheumatol 71. 2019/03/09 ed:1319-1328 (2019)
  4. Back M, Jayamanne D, Brazier D, Bailey DL, Hsiao E, Guo L, Wheeler H. Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. J Clin Neurosci 59. 2018/11/18 ed:68-74 (2019)
  5. Back M, Jayamanne DT, Brazier D, Newey A, Bailey DL, Schembri GP, Hsiao E, Khasraw M, Wong M, Kastelan M, Guo L, Clarke S, Wheeler H. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. J Med Imaging Radiat Oncol 63. 2019/01/25 ed:272-280 (2019)
  6. Chan DL, Bernard E, Schembri G, Roach P, Johnson M, Pavlakis N, Clarke SJ, Bailey DL. High metabolic tumour volume on FDG PET predicts poor survival from neuroendocrine neoplasms. Neuroendocrinology. 2019/11/12 ed (2019)
  7. Al-Aamria M, Al-Balushia N, Bailey DL. Estimation of Radiation Exposure to Workers During [(18)F] FDG PET/CT Procedures at Molecular Imaging Center, Oman. J Med Imaging Radiat Sci 50. 2019/08/27 ed:565-570 (2019)
  8. Back M, Jayamanne D, Brazier D, Newey A, Bailey D, Schembri G, Hsiao E, Khasraw M, Wong M, Kastelan M, Brown C, Wheeler H. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlenther Onkol. 2019/04/28 ed (2019)
  9. Campbell DH, Sabanathan D, Gurney H, Gillatt D, Trifunovic M, Poursoultan P, Ho Shon K, Mackay T, Bailey DL, Roach PJ, Walsh BJ. Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial. J Clin Oncol 37 (2019)
  10. Ryu H, Meikle SR, Willowson KP, Eslick EM, Bailey DL. Performance evaluation of quantitative SPECT/CT using NEMA NU 2 PET methodology. Phys Med Biol 64. 2019/06/18 ed:145017 (2019)
  1. Bailey DL, Pichler BJ, Guckel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougere C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T. Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tubingen, Germany. Mol Imaging Biol 20. 2017/10/04 ed:4-20 (2018)
  2. Bailey DL, Hofman MS, Forwood NJ, O'Keefe GJ, Scott AM, van Wyngaardt WM, Howe B, Kovacev O, Francis RJ. Accuracy of Dose Calibrators for Gallium-68 PET Imaging: Unexpected Findings in a Multi-Centre Clinical Pre-Trial Assessment. J Nucl Med 59. 2018/01/13 ed:636–638 (2018)
  3. Eslick EM, Stevens MJ, Bailey DL. SPECT V/Q in Lung Cancer Radiotherapy Planning. Semin Nucl Med 49. 2018/12/14 ed:31-36 (2018)
  4. Forwood N, Willowson KP, Tapner M, Bailey DL. Assessment of the relative contribution of volume and concentration changes in Yttrium-90 labelled resin microspheres on ionization chamber measurements. Australas Phys Eng Sci Med 40. 2017/11/18 ed:943-948 (2018)
  5. Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018/05/08 ed (2018)
  6. Willowson KP, Ryu H, Jackson P, Singh A, Eslick EM, Bailey DL. A Comparison of 2D and 3D Kidney Absorbed Dose Measures in Patients Receiving 177Lu-DOTATATE. Asia Ocean J Nucl Med Biol 6:113-119 (2018)
  7. Gholami Y, Willowson KP, Forwood N, J, Harvie R, Hardcastle N, Bromley R, Ryu H, Yuen S, Howell V, Kuncic Z, Bailey DL. Comparison of radiobiological parameters for 90Y Radionuclide Therapy (RNT) and External Beam Radiotherapy (EBRT) in vitro. Eur J Nucl Med Mol Imag Physics 5:18 (2018)
  8. Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, De Abreu Lourenco R, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018/05/05 ed (2018)
  9. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E, Commonwealth Neuroendocrine Tumour Collaboration Follow-up Working G. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018/07/29 ed (2018)
  10. Chan DL, Hsiao E, Schembri G, Bailey DL, Roach PJ, Lee A, Jayamanne D, Ghasemzadeh M, Hayes A, Cook R, Parkinson J, Drummond JP, Ibbett I, Wheeler HR, Back M. FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes - A pilot study. J Clin Neurosci. 2018/09/24 ed (2018)
  11. Eslick EM, Kipritidis J, Gradinscak D, Stevens MJ, Bailey DL, Harris B, Booth JT, Keall PJ. CT ventilation imaging derived from breath hold CT exhibits good regional accuracy with Galligas PET. Radiother Oncol 127. 2018/01/02 ed:267-273 (2018)
  12. Jaymanne DT, Kaushal S, Chan DLH, Schembri G, Brazier D, Bailey DL, Wheeler H, Back M. Utilizing 18F-fluoroethyl-l-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI. J Med Imaging Radiat Oncol 62. 2017/10/06 ed:122-127 (2018)
  13. Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following (177)Lu-DOTATATE ('Lutate') therapy. EJNMMI Phys 5. 2018/12/21 ed:33 (2018)
  1. Willowson KP, Bernard EJ, Maher R, Clarke SJ, Bailey DL. Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study. Asia Oceania J Nucl Med Biol 5:66-69 (2017)
  2. Chan DLH, Pavlakis N, Schembri G, Bernard E, Hsiao E, Hayes AR, Barnes T, Diakos C, Khasraw M, Samra J, Eslick EM, Roach PJ, Engel A, Clarke SJ, Bailey DL. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance Theranostics 7:1149-1158 (2017)
  3. Chan DLH, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol 113:268-282 (2017)
  4. Gzell C, Back M, Wheeler H, Bailey DL, Foote M. Radiotherapy in Glioblastoma: the Past, the Present and the Future. Clin Oncol (R Coll Radiol) 29. 2016/10/17 ed:15-25 (2017)
  5. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017/09/06 ed (2017)
  6. Back M, LeMottee M, Crasta C, Bailey DL, Wheeler H, Guo L, Eade T. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma. Radiat Oncol 12. 2017/03/04 ed:46 (2017)
  7. Sammel AM, Hsiao E, Schrieber L, Janssen B, Youssef P, Fraser CL, Kuo CH, Dunn H, Bailey DL, Roach P, Schembri G, Bailey E, Nguyen K, Farmakis P, Laurent R. Fluorine-18 Fluoro-2-Deoxyglucose Positron Emission Tomography Uptake in the Superficial Temporal and Vertebral Arteries in Biopsy Positive Giant Cell Arteritis. J Clin Rheumatol 23. 2017/09/28 ed:443 (2017)
  8. Farrow CE, Salome CM, Harris BE, Bailey DL, Berend N, King GG. Peripheral Ventilation Heterogeneity Determines the Extent of Bronchoconstriction in Asthma. J Appl Physiol (1985). 2017/08/12 ed:jap 00640 02016 (2017)
THERANOSTICS Today & Tomorrow
Summary of Speech
The practice of theranostics has developed over the last twenty years from initially one or two targeted treatments for cancer management to now a large number of targets and “pan-cancer” developments as our understanding of oncogenes and the tumour microenvironment grows. Theranostics has become a mainstream, but rarely first-line, therapeutic strategy in many parts of the world. One of the unique features of the theranostic approach is that it provides both pre- and post-treatment imaging to assess targeting and to permit estimation of radiation dose delivered to organs at risk and cancer tissue to predict the likely magnitude of response. While many of the tools for precision treatments are already in place to translate this approach into personalised medicine for an individual we still must address some methodological issues such as limited spatial resolution in PET and SPECT and reducing the burden on patients and imaging facilities of studying uptake and retention at multiple timepoints. However, with many new targets emerging and exploration of alternative cytotoxic payloads such as alpha particles and Auger electrons the field of theranostics appears to have a bright future and ever expanding role in cancer management. This lecture will review the current status of theranostics and look at some of the many opportunities that exist for future improvements in treatment efficacy and ultimately outcomes.